Gallant Joel E
Division of Infectious Diseases, The Johns Hopkins University School of Medicine, 1830 E. Monument Street, Rm. 443, Baltimore, MD 21287, USA.
J Clin Virol. 2002 Dec;25(3):317-33. doi: 10.1016/s1386-6532(02)00024-0.
The use of antiretroviral therapy has improved the quality of life and has increased the survival of HIV-infected individuals. However, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The initial regimen provides the greatest chance for lasting suppression of viral load.
Appropriate selection of the initial antiretroviral regimen is critical. The growing number of drug classes allows healthcare providers to individualize treatment regimens. Factors influencing the selection of first-line therapy include baseline viral load and CD4 count, drug pharmacokinetics, potency, tolerability, safety, resistance and salvageability. Characteristics likely to affect adherence, such as regimen complexity and pill burden, must also be considered, as poor adherence is the most common cause of treatment failure.
The selection of the initial regimen requires consideration of several factors. Drugs from new classes as well as new drugs from existing classes with favorable resistance and side effect profiles are in various stages of development. Many of these drugs will enhance available options for initial therapy.
抗逆转录病毒疗法的使用提高了生活质量,并延长了HIV感染者的生存期。然而,病毒的快速突变以及随后耐药HIV变体的出现威胁着HIV治疗的长期疗效。初始治疗方案提供了持久抑制病毒载量的最大机会。
合理选择初始抗逆转录病毒治疗方案至关重要。药物种类的不断增加使医疗服务提供者能够制定个体化的治疗方案。影响一线治疗选择的因素包括基线病毒载量和CD4细胞计数、药物药代动力学、效力、耐受性、安全性、耐药性和挽救性。还必须考虑可能影响依从性的特征,如治疗方案的复杂性和服药负担,因为依从性差是治疗失败的最常见原因。
初始治疗方案的选择需要考虑多个因素。来自新类别以及具有良好耐药性和副作用特征的现有类别的新药正处于不同的研发阶段。这些药物中的许多将增加初始治疗的可用选择。